Skip to main content
. Author manuscript; available in PMC: 2020 Jun 1.
Published in final edited form as: Breast Cancer Res Treat. 2019 Feb 12;175(2):297–303. doi: 10.1007/s10549-019-05158-3

Fig. 3.

Fig. 3.

Change in spine BMD T-scores between baseline and 24 months in letrozole- and exemestane- treated patients homozygous for UGT2B17*2 gene deletion. Box and whisker plots of changes in BMD in spine in patients with UGT2B17*2/*2 stratified by AI.